Mouse study points to atorvastatin as adjunct in giardiasis

Version 1 — Brief

A new Frontiers in Veterinary Science study suggests atorvastatin, a widely used statin, may have value as an adjunct treatment for giardiasis, at least in a mouse model. Researchers used molecular docking plus an in vivo Swiss albino mouse experiment and found that atorvastatin showed dose-dependent antiparasitic activity, though it was less effective than metronidazole at reducing intestinal trophozoite counts. At the higher dose tested, atorvastatin reduced trophozoites by about 41.5%, compared with 71.7% for metronidazole. Where atorvastatin stood out was inflammation control: the drug was associated with lower intestinal iNOS and IL-6 expression, improved intestinal architecture, less liver pathology, and lower ALT levels. The authors frame it as a possible dual-action or adjunct therapy, not a replacement for standard treatment. (frontiersin.org)

Why it matters: For veterinary professionals, the study adds to the growing drug-repurposing conversation around Giardia, especially as resistance and treatment limitations keep attention on alternatives to nitroimidazoles. That said, this is still an early, preclinical mouse study, and current veterinary practice remains anchored to approved and established therapies. In the U.S., FDA approved Ayradia (metronidazole oral suspension) in dogs in October 2023 as the first approved animal drug for Giardia duodenalis infection in any animal species. Giardia also remains broadly relevant across animal health because it is a common zoonotic parasite in mammals, with a recent meta-analysis estimating a 13.6% global pooled prevalence in nonhuman mammalian hosts. (fda.gov)

What to watch: The next step is whether follow-up studies test atorvastatin in target veterinary species, in combination with standard therapy, and with safety and dosing data that could support any clinical use. (frontiersin.org)